Portfolio company
Finaldose
United Kingdom
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
3 investors
Sectors
About
This company develops programmable medicines that identify and destroy cancerous cells using DNA signatures for patients with genetic mutations.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
DualTPharma
This company develops bacteria-based drug delivery systems to transport immunotherapies into solid tumours for cancer patients.
Flindr Therapeutics
This company develops small molecule inhibitors for the precision treatment of cancer patients with specific tumor and host factors.
Foundation Medicine
This company develops genomic profiling tests to help doctors and researchers identify treatment options for cancer patients.
Fore Bio
This biotechnology company develops precision oncology therapies and small-molecule inhibitors for patients with unaddressed tumour mutations and hard-to-treat cancers.
Stratosvir
This company develops viral immunotherapies for late-stage cancer patients to target solid tumours through systemic delivery and immune system activation.
Enedra Therapeutics Ltd
This company develops precision medicines and biomarkers to treat advanced, genetically heterogeneous cancers for patients with drug-resistant tumours.
Flindr
The company develops small molecule inhibitors for precision oncology treatments to improve outcomes for cancer patients.
NaDeNo
This company develops a nanotechnology drug delivery platform for pharmaceutical partners to encapsulate hydrophobic small molecule drugs for targeted cancer treatments.